NGEN
NervGen Pharma·NASDAQ
--
--(--)
--
--(--)
NGEN fundamentals
During Q4 2025, NervGen Pharma (NGEN) reported revenue of --, a YoY change of 0.00%. Net income was -19.62M, a YoY change of -237.84%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2024 | Q4,2024 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jul 1, 2024 | Oct 1, 2024 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Sep 30, 2024 | Dec 31, 2024 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Pretax Income From Continuing Operations | -3.92M -- | -5.81M -- | -2.98M +23.87% | -19.62M -237.84% | -- -- |
Net Income | -3.92M -- | -5.81M -- | -2.98M +23.87% | -19.62M -237.84% | -- -- |
Total Comprehensive Income | -3.92M -- | -5.81M -- | -2.98M +23.87% | 12.55M +316.05% | -- -- |
Basic EPS | -0.06 -- | -0.08 -- | -0.04 +33.33% | -0.25 -212.50% | -- -- |
Diluted EPS | -0.06 -- | -- -- | -0.04 +33.33% | -- -- | -- -- |
You can ask Aime
What does NervGen Pharma do and what are its main business segments?What is NervGen Pharma's gross profit margin?What is the revenue and EPS growth rate for NervGen Pharma year over year?What were the key takeaways from NervGen Pharma's earnings call?What were the key takeaways from NervGen Pharma’s earnings call?What is NervGen Pharma's latest dividend and current dividend yield?Did NervGen Pharma beat or miss consensus estimates last quarter?What is the market's earnings forecast for NervGen Pharma next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
